AVG Stock Overview
Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Avantor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.60 |
| 52 Week High | US$22.60 |
| 52 Week Low | US$17.55 |
| Beta | 1.32 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -27.10% |
| 5 Year Change | 66.32% |
| Change since IPO | 75.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVG | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.02% |
| 1Y | n/a | 2.7% | 8.2% |
Return vs Industry: Insufficient data to determine how AVG performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how AVG performed against the German Market.
Price Volatility
| AVG volatility | |
|---|---|
| AVG Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: AVG has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AVG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1904 | 14,500 | Michael Stubblefield | www.avantorsciences.com |
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.
Avantor, Inc. Fundamentals Summary
| AVG fundamental statistics | |
|---|---|
| Market cap | €12.98b |
| Earnings (TTM) | €238.71m |
| Revenue (TTM) | €6.30b |
54.4x
P/E Ratio2.1x
P/S RatioIs AVG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVG income statement (TTM) | |
|---|---|
| Revenue | US$6.87b |
| Cost of Revenue | US$4.56b |
| Gross Profit | US$2.31b |
| Other Expenses | US$2.05b |
| Earnings | US$260.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 26, 2024
| Earnings per share (EPS) | 0.38 |
| Gross Margin | 33.63% |
| Net Profit Margin | 3.79% |
| Debt/Equity Ratio | 98.5% |
How did AVG perform over the long term?
See historical performance and comparison